tiprankstipranks

ProQR Therapeutics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $5 price target ProQR represents a “true” biotech investment given its early-stage, emerging technology with “a plethora of potential applications,” ovel first in class targets and a wide array of strategic optionality for the company, but over the last few years investors have increasingly focused on derisked targets and indications, which is why the stock is trading at cash despite what the firm calls “significant internal progress” and external validation.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue